INTERVIEWS MIT REFERENTEN
Genetics in psoriasis and atopic dermatitis
What are some of the new findings regarding genetics in psoriasis and atopic dermatitis?
How can pharmacogenomics help the dermatologist in choosing the right drug for the right patient?
Target-oriented therapy in psoriatic arthritis
What factors influence the clinician’s choice of biologic agents?
What recent developments are likely to affect the treatment of psoriatic arthritis?
How important is it for dermatologists to screen for psoriatic arthritis and refer to rheumatologists?
Therapeutic drug monitoring in biologics
How can individualized therapy be defined?
Does therapeutic drug monitoring have a role when considering individualized therapy with biologics in major inflammatory skin diseases?
Is "drug survival" a useful metric to assess the efficacy of biological therapy for psoriasis in daily practice?
Innovative phototherapeutic approaches in psoriasis and atopic dermatitis
What innovative phototherapeutic approaches are being used in psoriasis and atopic dermatitis?
What role do different types of lasers play in the treatment of psoriasis and atopic dermatitis?
What new developments are taking place with regards to UV-free light therapy?
Epidemiology of major inflammatory skin diseases in emerging countries
How is the epidemiology of major inflammatory skin diseases changing in emerging countries?
How does dermatological practice vary in advanced countries compared to emerging countries?
Autoimmunity in psoriasis
What are the most recent findings concerning psoriasis and autoimmunity?
Several autoimmune diseases appear to be associated with psoriasis. What does the recent evidence add to the current debate on whether psoriasis is a primary autoimmune disease or a secondary pathology that evolves into autoimmunity as in other chronic inflammatory diseases?
What new data on autoimmunity will likely add to the current treatment armamentarium through protective and prophylactic antigen-specific modalities?
Which drug for which patient?
How does the clinician determine which drug is best suited for each patient?
Does having a wider choice of biologics allow for better treatment options and improved outcomes?
Which comorbidities should physicians take into consideration when treating patients with psoriasis?
Comorbidities in psoriasis
What comorbidities modify the therapeutic approach and management of psoriasis?
What novel therapeutic agents can be expected in psoriasis and atopic dermatitis from SPIN 2019?
Transitioning between biologic agents
What clinical situations require optimization of therapy?
When would you consider a wash out for a biologic agent?
At what interval would you consider transitioning to a new biologic agent after previous failure of a biologic agent?